Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells
Kyu Kwang Kim(University of Rochester Medical Center), Richard G. Moore(University of Rochester Medical Center)
Cited by 62
Related Papers
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
|BMC Cancer|2012|40
Role of trypsin and protease-activated receptor-2 in ovarian cancer
|PLoS ONE|2020|40
Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
|Scientific Reports|2015|22
Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model
|PLoS ONE|2012|20
Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines
|Scientific Reports|2020|20